BioSpace News Archive

Abbott’s new point-of-care test for the novel coronavirus that causes COVID-19 was approved by the U.S. Food and Drug Administration (FDA) under Emergency Use Authorization (EUA).

The brands will also donate $1 for every use of hashtag #ShareASquareCanada and provide product to those in need

Edwards Lifesciences Corporation announced it will temporarily pause new enrollments in its active pivotal clinical trials of transcatheter mitral and tricuspid therapies, in response to the urgent COVID-19 response around the globe.

Ryvu Therapeutics (WSE: RVU), a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted an orphan drug designation (ODD) to Ryvu’s SEL120, for the treatment of patients with acute myelo

Phase 3 VICTORIA Trial is the First Contemporary Outcomes Study Focused Exclusively on a Chronic Heart Failure Patient Population Following a Worsening Event

International Christian Relief Organization Responds at the Epicenter of the Coronavirus in the U.S.

- Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials showed inclisiran reduced low-density lipoprotein-cholesterol (LDL-C) by 51% at 17 months(1) - Prespecified exploratory analysis based on safety reporting from the three trials, showed fewer major adverse cardiovascular events (MACE) with inclisiran compared to placebo(1) - The data are consistent with LDL-C lowering as a strong surrogate for improved patient cardiovascular outcomes(2)

Disaster Management Group, a South Florida-based disaster recovery firm, announced DMGtest, a screening tool for COVID-19 that gives results in 15 minutes.

Study Met Primary Endpoint (Change From Baseline in LDL-C) and All Secondary Endpoints Repatha is the First PCSK9 Inhibitor to Demonstrate LDL-C Lowering Results in People Living with HIV [28-March-2020] THOUSAND OAKS, Calif. , March 28, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the Evolocuma B E ffect on LDL-C Lower I

XARELTO® has the potential to be the first anticoagulant in 20 years(i) to show a benefit in these high-risk patients Two major Phase 3 trials have evaluated XARELTO® vascular dose plus aspirin in treating patients with atherosclerotic disease [28-March-2020] RARITAN, N.J. , March 28, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson &